CorMedix
CRMD · Nasdaq · United States
Share price · CRMD
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when CRMD's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 30 Oct 2026-25.5%
Nothing announced by CRMD that day or the session before.
- 29 Oct 2026-6.8%
Nothing announced by CRMD that day or the session before.
- 14 Aug 2026-7.4%
- 13 Aug 2026+14.6%
- 1 Jul 2026+7.9%
- 25 Jun 2026-8.0%
- 18 May 2026+4.8%
Nothing announced by CRMD that day or the session before.
- 14 May 2026+5.7%
- 27 Apr 2026+5.4%
- 8 Jan 2026-32.8%
Share of unusual movement by asset
For each asset, the share of CRMD's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
| Other company news (earnings, financing, releases naming no asset) | — | 57% |
| Sessions with no dated event | — | 43% |
No dated announcements about its assets since 2 Jul 2024.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
Taurolidine/heparin(Defencath / Neutrolin) | Approved | Antimicrobial/antithrombotic catheter lock solutionSmall molecule | Chronic Kidney Disease |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2028 (1)
January 2028 (1)
What to watch
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $55M | $7.0M | $356M+ $0 short-term inv. | $15M$90M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $6.7M | $258M+ $0 short-term inv. | —$86M operating cash flow | report ↗ |
| 2026-Q1 | — | $7.2M | $179M+ $0 short-term inv. | —$42M operating cash flow | report ↗ |
| 2025-Q3 | $104M | $5.1M | $49M+ $7.2M short-term inv. | —$31M operating cash flow | report ↗ |
| 2025-Q2 | $40M | $2.4M | $159M+ $31M short-term inv. | —$30M operating cash flow | report ↗ |
| 2025-Q1 | $39M | $3.2M | $66M+ $11M short-term inv. | —$20M operating cash flow | report ↗ |
| 2024-Q3 | $11M | $0.7M | $35M+ $11M short-term inv. | $2.8M-$14M operating cash flow | report ↗ |
| 2024-Q2 | $0.8M | $0.7M | $29M+ $17M short-term inv. | $14M-$14M operating cash flow | report ↗ |
| 2024-Q1 | — | $0.8M | $35M+ $23M short-term inv. | $14M-$17M operating cash flow | report ↗ |
| 2023-Q3 | — | $2.7M | $54M+ $33M short-term inv. | $9.7M-$8.7M operating cash flow | report ↗ |
| 2023-Q2 | — | $4.8M | $20M+ $33M short-term inv. | $11M-$8.6M operating cash flow | report ↗ |
| 2023-Q1 | — | $3.4M | $26M+ $30M short-term inv. | $11M-$10M operating cash flow | report ↗ |
| 2022-Q3 | <$0.1M | $2.3M | $43M+ $16M short-term inv. | $6.8M-$6.0M operating cash flow | report ↗ |
| 2022-Q2 | <$0.1M | $3.2M | $49M+ $16M short-term inv. | $7.6M-$5.5M operating cash flow | report ↗ |
| 2022-Q1 | <$0.1M | $2.3M | $46M+ $16M short-term inv. | $7.0M-$6.7M operating cash flow | report ↗ |
| 2021-Q3 | <$0.1M | $4.7M | $67M+ $5.7M short-term inv. | $8.6M-$5.5M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $312M | $19M | $146M+ $3.7M short-term inv. | —$175M operating cash flow | report ↗ |
For the full year 2025, CorMedix reported revenue of $311.71M, up 617.1% YoY, with R&D spend of $19.33M, up 390.6% YoY. Cash and equivalents stood at $145.82M, and the company recorded net income of $163.06M.
CorMedix reiterated 2026 guidance of net revenue between $300M and $320M and adjusted EBITDA between $100M and $125M. Clinical milestones include Phase 3 ReSPECT data for REZZAYO expected in Q2 2026, and an ongoing Phase 3 study of taurolidine/heparin catheter lock solution in TPN patients with targeted completion in the first half of 2027. The company also highlighted the integration of its August 2025 Melinta acquisition and a newly authorized $75M share repurchase program.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $43M | $3.9M | $41M+ $11M short-term inv. | $4.5M-$51M operating cash flow | report ↗ |
| 2023-FY | — | $13M | $44M+ $32M short-term inv. | $12M-$38M operating cash flow | report ↗ |
| 2022-FY | $0.1M | $11M | $43M+ $16M short-term inv. | $7.4M-$24M operating cash flow | report ↗ |
| 2021-FY | $0.2M | $13M | $54M+ $12M short-term inv. | $7.0M-$21M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 2 purchases ($513K), 7 sales ($2.3M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-16 | Kaplan Myron · director | Open-market purchase | 25,000 | $4.88 | $122K | Form 4 |
| 2026-11-13 | Todisco Joseph · director, Chief Executive Officer | Open-market purchase | 80,000 | $4.89 | $391K | Form 4 |
| 2026-09-18 | Dillione Janet · director | Option exercise | 48,909 | — | — | Form 4 |
| 2026-09-18 | Dillione Janet · director | Option exercise (derivative) | 48,909 | — | — | Form 4 |
| 2026-08-29 | Zelnick Kaufman Beth · Chief Legal Officer | Tax withholding | 8,424 | $8.30 | $70K | Form 4 |
| 2026-08-29 | Hurlburt Elizabeth · Chief Operating Officer | Tax withholding | 8,076 | $8.30 | $67K | Form 4 |
| 2026-08-29 | Blum Susan · Chief Financial Officer | Tax withholding | 8,424 | $8.30 | $70K | Form 4 |
| 2026-02-04 | Todisco Joseph · director, Chief Executive Officer | Award / grant | 77,156 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 185 reporting institutions held 40.6M shares ($272.6M, 52.0% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Deep Track Capital, LP | 6,274,076 | $42.6M |
| 2 | BlackRock, Inc. | 5,967,575 | $40.5M |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 3,129,656 | $21.3M |
| 4 | STATE STREET CORP | 2,191,843 | $14.9M |
| 5 | ROYCE & ASSOCIATES LP | 1,887,532 | $12.8M |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 1,816,907 | $12.3M |
| 7 | UBS Group AG | 1,538,245 | $10.4M |
| 8 | OBERWEIS ASSET MANAGEMENT INC/ | 1,211,115 | $8.2M |
| 9 | Alyeska Investment Group, L.P. | 850,000 | $5.8M |
| 10 | VANGUARD PORTFOLIO MANAGEMENT LLC | 742,571 | $5.0M |
| 11 | KENNEDY CAPITAL MANAGEMENT LLC | 673,302 | $4.6M |
| 12 | NORTHERN TRUST CORP | 637,683 | $4.3M |
| 13 | Palisades Investment Partners, LLC | 610,148 | $4.1M |
| 14 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 602,966 | $4.1M |
| 15 | Trexquant Investment LP | 560,637 | $3.8M |